Promising Novel Biomarkers for Hepatocellular Carcinoma: Diagnostic and Prognostic Insights

The systemic therapy landscape for hepatocellular carcinoma is rapidly evolving, as the recent approvals of checkpoint inhibitor-based regimens such as atezolizumab–bevacizumab and durvalumab–tremelimumab in advanced disease have led to an expanding therapeutic armamentarium. The development of biom...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, James, Park, Robin, Kim, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362916/
https://www.ncbi.nlm.nih.gov/pubmed/37483311
http://dx.doi.org/10.2147/JHC.S341195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362916/
https://www.ncbi.nlm.nih.gov/pubmed/37483311
http://dx.doi.org/10.2147/JHC.S341195

Ejemplares similares